SIGN UP
LOG IN
News
JW (Cayman) Therapeutics
--
--
0.00%
Weekly Report: what happened at JW (Cayman) Therapeutics last week (0623-0627)?
Weekly Report · 6d ago
Weekly Report: what happened at JW (Cayman) Therapeutics last week (0616-0620)?
Weekly Report · 06/22 22:04
Top 3 Asian Penny Stocks With Market Caps Over US$100M To Watch
Simply Wall St · 06/22 22:01
Weekly Report: what happened at JW (Cayman) Therapeutics last week (0609-0613)?
Weekly Report · 06/15 22:04
Weekly Report: what happened at JW (Cayman) Therapeutics last week (0602-0606)?
Weekly Report · 06/08 22:04
Weekly Report: what happened at JW (Cayman) Therapeutics last week (0526-0530)?
Weekly Report · 06/01 22:04
JW (Cayman) Therapeutics Co. Ltd (HKG:2126) Held Back By Insufficient Growth Even After Shares Climb 34%
Simply Wall St · 05/29 23:16
Weekly Report: what happened at JW (Cayman) Therapeutics last week (0519-0523)?
Weekly Report · 05/25 22:04
Weekly Report: what happened at JW (Cayman) Therapeutics last week (0512-0516)?
Weekly Report · 05/18 22:04
Weekly Report: what happened at JW (Cayman) Therapeutics last week (0505-0509)?
Weekly Report · 05/11 22:04
Weekly Report: what happened at JW (Cayman) Therapeutics last week (0428-0502)?
Weekly Report · 05/04 22:04
Weekly Report: what happened at JW (Cayman) Therapeutics last week (0421-0425)?
Weekly Report · 04/27 22:05
Weekly Report: what happened at JW (Cayman) Therapeutics last week (0414-0418)?
Weekly Report · 04/20 22:05
Weekly Report: what happened at JW (Cayman) Therapeutics last week (0407-0411)?
Weekly Report · 04/13 22:05
Market Cool On JW (Cayman) Therapeutics Co. Ltd's (HKG:2126) Revenues Pushing Shares 37% Lower
Simply Wall St · 04/08 00:54
Weekly Report: what happened at JW (Cayman) Therapeutics last week (0331-0404)?
Weekly Report · 04/06 22:04
Weekly Report: what happened at JW (Cayman) Therapeutics last week (0324-0328)?
Weekly Report · 03/30 22:04
JW (CAYMAN) THERAPEUTICS FY GROSS MARGIN 48.9%
Reuters · 03/27 10:25
Weekly Report: what happened at JW (Cayman) Therapeutics last week (0317-0321)?
Weekly Report · 03/23 22:05
About JW (Cayman) Therapeutics
JW (Cayman) Therapeutics Co Ltd is a company primarily engaged in research and development, manufacturing, and marketing of cellular immunotherapy products. The Company has built an integrated platform for product development in cell immunotherapy, as well as a product pipeline covering hematologic malignancies, solid tumors and autoimmune diseases. The Company’s main product, Carteyva, is an autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) cell immunotherapy product independently developed by the Company based on a CAR-T cell process platform of Juno (a Bristol Myers Squibb company). The Company mainly conducts its business in the domestic market.
MoreRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.